Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.28
+$1.53 · +7.03%
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Previous close
$23.28
+$1.53 · +7.03%
After-hours
$23.28
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Day range
Current $23.28
52-week range
Current $23.28
Regular session · ET · Market data may be delayed.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Day range
Current $23.28
52-week range
Current $23.28
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 66.31M USD |
| Selling, general, and administrative | 20.98M USD |
| Operating expenses | 87.29M USD |
| Interest income | 11.4M USD |
| Depreciation and amortization | 1.41M USD |
| Operating income | −87.29M USD |
| Net income | −74.88M USD |
Company facts updated Sep 11, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.72M0.00%2.3T USD0.03%$373.24-0.62%
Vanguard Extended Market ETFVXF3.39M0.00%93.7B USD0.05%$236.16-1.05%
Schwab U.S. Small-Cap ETFSCHA1.57M0.01%22.62B USD0.03%$33.65-1.32%
Schwab U.S. Broad Market ETFSCHB275.67K0.00%44.07B USD0.03%$29.23-0.58%
Vanguard Russell 2000 ETFVTWO161.78K0.00%17.4B USD0.06%$116.34-1.00%
Hypatia Women CEO ETFWCEO56.78K0.48%5.55M USD0.85%$37.8899-0.88%
Vanguard Russell 2000 Growth ETFVTWG15.92K0.00%1.7B USD0.06%$266.89-1.41%
T. Rowe Price Innovation Leaders ETFTNXT8.55K0.05%18.43M USD0.49%$28.0828-1.02%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHASchwab U.S. Broad Market ETFSCHBVanguard Russell 2000 ETFVTWOHypatia Women CEO ETFWCEOVanguard Russell 2000 Growth ETFVTWGT. Rowe Price Innovation Leaders ETFTNXTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
